A randomized, multicenter, phase 2 trial comparing CAPTEM versus FOLFIRI as second-line treatment for MGMT-methylated, RAS-mutated metastatic colorectal cancer patients

Cancer Patients ◽

Line Treatment ◽

Second Line ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase ◽

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial

Annals of Oncology ◽

10.1093/annonc/mdz155.088 ◽

2019 ◽

Vol 30 ◽

pp. iv23-iv24 ◽

Cited By ~ 3

Author(s):

A. Fernández Montes ◽

N. Martinez Lago ◽

J. De la Cámara Gómez ◽

M. Covela Rúa ◽

A. Cousillas Castiñeiras ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Treatment Phase ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

First Line ◽

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial

Cancer Communications ◽

10.1186/s40880-019-0374-8 ◽

2019 ◽

Vol 39 (1) ◽

pp. 28 ◽

Cited By ~ 1

Author(s):

Yuankai Shi ◽

Jin Li ◽

Jianming Xu ◽

Yan Sun ◽

Liwei Wang ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Iii ◽

Line Treatment ◽

Second Line ◽

Wild Type ◽

Open Label ◽

Phase Iii Trial ◽

Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients

Surgery Today ◽

10.1007/s00595-010-4432-8 ◽

2011 ◽

Vol 41 (8) ◽

pp. 1067-1074 ◽

Cited By ~ 13

Author(s):

Mitsukuni Suenaga ◽

Satoshi Matsusaka ◽

Masashi Ueno ◽

Noriko Yamamoto ◽

Eiji Shinozaki ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Line Treatment ◽

Second Line ◽

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

International Journal of Oncology ◽

10.3892/ijo.2013.2179 ◽

2013 ◽

Vol 44 (1) ◽

pp. 17-26 ◽

Cited By ~ 6

Author(s):

GEMMA BRUERA ◽

KATIA CANNITA ◽

ALDO VICTOR GIORDANO ◽

ROBERTO VICENTINI ◽

CORRADO FICORELLA ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Line Treatment ◽

Second Line ◽

First Line ◽

Triplet Chemotherapy ◽

Triplet Chemotherapy Plus Bevacizumab

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial

Digestive and Liver Disease ◽

10.1016/j.dld.2020.11.031 ◽

2020 ◽

Author(s):

Julien Taïeb ◽

Thierry André ◽

Farid El Hajbi ◽

Emilie Barbier ◽

Clémence Toullec ◽

...

Keyword(s):

Colorectal Cancer ◽

Microsatellite Instability ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Annals of Oncology ◽

10.1093/annonc/mdw335.14 ◽

2016 ◽

Vol 27 ◽

pp. iv43

Author(s):

D. Rossini ◽

M. Casagrande ◽

R. Moretto ◽

F. Loupakis ◽

C. Cremolini ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Pooled Analysis ◽

Line Treatment ◽

Targeted Agents ◽

First Line ◽

Safety And Efficacy ◽

First Line Treatment

Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer

Cancer ◽

10.1002/cncr.31552 ◽

2018 ◽

Vol 124 (15) ◽

pp. 3118-3126 ◽

Cited By ~ 10

Author(s):

Hanna K. Sanoff ◽

Richard M. Goldberg ◽

Anastasia Ivanova ◽

Seamus O'Reilly ◽

Samer S. Kasbari ◽

...

Keyword(s):

Colorectal Cancer ◽

Second Line ◽

Phase 2 ◽

Second Line Therapy ◽

Double Blind ◽

Phase 2 Trial ◽

Line Therapy

A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

British Journal of Cancer ◽

10.1038/s41416-019-0537-z ◽

2019 ◽

Vol 121 (5) ◽

pp. 378-383 ◽

Cited By ~ 1

Author(s):

Elena Elez ◽

Carles Pericay ◽

Manuel Valladares-Ayerbes ◽

Inmaculada Bando ◽

Maria Jose Safont ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Salvage Therapy ◽

Phase 2 ◽

Wild Type ◽

Exon 2 ◽

Phase 2 Study ◽

Kras Exon

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(10)70175-3 ◽

2010 ◽

Vol 11 (9) ◽

pp. 845-852 ◽

Cited By ~ 182

Author(s):

Gianluca Masi ◽

Fotios Loupakis ◽

Lisa Salvatore ◽

Lorenzo Fornaro ◽

Chiara Cremolini ◽

...

Keyword(s):

Colorectal Cancer ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

First Line Treatment